EBioMedicine (Jul 2017)

Combined Mass Spectrometry Imaging and Top-down Microproteomics Reveals Evidence of a Hidden Proteome in Ovarian Cancer

  • Vivian Delcourt,
  • Julien Franck,
  • Eric Leblanc,
  • Fabrice Narducci,
  • Yves-Marie Robin,
  • Jean-Pascal Gimeno,
  • Jusal Quanico,
  • Maxence Wisztorski,
  • Firas Kobeissy,
  • Jean-François Jacques,
  • Xavier Roucou,
  • Michel Salzet,
  • Isabelle Fournier

DOI
https://doi.org/10.1016/j.ebiom.2017.06.001
Journal volume & issue
Vol. 21, no. C
pp. 55 – 64

Abstract

Read online

Background: Recently, it was demonstrated that proteins can be translated from alternative open reading frames (altORFs), increasing the size of the actual proteome. Top-down mass spectrometry-based proteomics allows the identification of intact proteins containing post-translational modifications (PTMs) as well as truncated forms translated from reference ORFs or altORFs. Methods: Top-down tissue microproteomics was applied on benign, tumor and necrotic-fibrotic regions of serous ovarian cancer biopsies, identifying proteins exhibiting region-specific cellular localization and PTMs. The regions of interest (ROIs) were determined by MALDI mass spectrometry imaging and spatial segmentation. Findings: Analysis with a customized protein sequence database containing reference and alternative proteins (altprots) identified 15 altprots, including alternative G protein nucleolar 1 (AltGNL1) found in the tumor, and translated from an altORF nested within the GNL1 canonical coding sequence. Co-expression of GNL1 and altGNL1 was validated by transfection in HEK293 and HeLa cells with an expression plasmid containing a GNL1-FLAG(V5) construct. Western blot and immunofluorescence experiments confirmed constitutive co-expression of altGNL1-V5 with GNL1-FLAG. Conclusions: Taken together, our approach provides means to evaluate protein changes in the case of serous ovarian cancer, allowing the detection of potential markers that have never been considered.

Keywords